SEC Filing Summary

Richard Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc., reported a transaction involving 35 shares of Common Stock acquired on June 15, 2026. The acquisition was part of a grant of 562 Restricted Stock Units (RSUs) on March 15, 2023, which vest over time. Each RSU represents a contingent right to one share of the Issuer's Common Stock. Following this transaction, Mr. Steinhart holds 26,335 shares of Common Stock directly and 212 RSUs.